Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

-Given standard of care

-Given standard of care

-Given standard of care

-Will be provided by Bristol Myers Squibb

-Baseline, week 5, surgery, and at time of relapse (optional)

-Time of port placement (baseline), time of surgery, and time of recurrence (optional)

-Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)